Tags |
|
|
Links |
|
|
Actual - Patent History, Part II
The Patent Act was further amended in 1836, when it was realized that a more thorough description was needed; without a thor
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ough description of the invention, it was harder to file a lawsuit against someone accused of illegally using the patent.
A
A
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
ter this amendment was made to the way in which patents are described, the patent act underwent major changes in 1836. These
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
changes were the result of complaints lodged against patented items, which were not found to be new ideas. Eventually, the p
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
tent laws were changed to reflect that an invention had to be novel.
Another component of the law was changed during 1836,
Another component of the law was changed during 1836,
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
with the removal of patent rules stating that a person from another country had to be living in the United States for two ye
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
rs. After 1836, anyone residing in the United States was able to apply for a patent. However, the application fee of United
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
tates citizens was less than someone from overseas.
In 1839, the patent rules were further changed to give the inventor the
In 1839, the patent rules were further changed to give the inventor the
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ability to appeal the negative decision of the Patent Office. The first patent for a design was granted in 1849; at the same
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
time, the stipulation that an invention not be obvious was added to the rules. In 1930 the Patent Office began accepting pa
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ents for plants, as horticulturists continued to develop new breeds and hybrids of commercial value.
These ongoing revision
These ongoing revision
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
to the law proceeded until around 1952, when the regulatory regime stabilized and the rules did not change much from year t
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
year, until the next major change arrived in the form of the Patent Reform Act of 2005. The most notable change to the rule
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
s is that the patent applicant does not have to be the earliest person to invent the idea, but rather the earliest person to
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
file the application. However, this reform does stipulate that the earliest person filing cannot steal the idea from another
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
inventor. They must have each independently conceived the idea. The earliest application to file is now given priority, rath
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
r than the earliest work on the idea, largely because the Patent Office can easily determine the date of a filing, and canno
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
t easily determine the date when an idea was actually invented.
Future changes to patent law are likely, given that this ex
Future changes to patent law are likely, given that this ex
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
eriment in intellectual property law is still relatively new by the standards of law. Inventors and innovators should be awa
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
e of the possibility for changes in the law going forward.
History has proven that patents are an integral part of business
History has proven that patents are an integral part of business
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/130700/actual-Patent-History-Part-II.html">Patent History, Part II</a>
BB link (for phorums):
[url=http://www.actual.org.ua/article/130700/actual-Patent-History-Part-II.html]Patent History, Part II[/url]
Related Articles:
How to Jumpstart Your Site's Exposure: Pay-per-clicking
Five Hot Tips To Get Out Of Debt Forever
Bookmark it:
|